<!DOCTYPE html>
<html lang="en">

<head>
  <title>Stable Ischemic Heart Disease (Incomplete) | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />

  <script src='/peripheral_brain/javascript/mermaid.js'></script>
  <link rel="stylesheet" href="/peripheral_brain/css/mermaid.css" />

  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="57x57" href="/peripheral_brain/favicons/apple-icon-57x57.png">
  <link rel="apple-touch-icon" sizes="60x60" href="/peripheral_brain/favicons/apple-icon-60x60.png">
  <link rel="apple-touch-icon" sizes="72x72" href="/peripheral_brain/favicons/apple-icon-72x72.png">
  <link rel="apple-touch-icon" sizes="76x76" href="/peripheral_brain/favicons/apple-icon-76x76.png">
  <link rel="apple-touch-icon" sizes="114x114" href="/peripheral_brain/favicons/apple-icon-114x114.png">
  <link rel="apple-touch-icon" sizes="120x120" href="/peripheral_brain/favicons/apple-icon-120x120.png">
  <link rel="apple-touch-icon" sizes="144x144" href="/peripheral_brain/favicons/apple-icon-144x144.png">
  <link rel="apple-touch-icon" sizes="152x152" href="/peripheral_brain/favicons/apple-icon-152x152.png">
  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-icon-180x180.png">
  <link rel="icon" type="image/png" sizes="192x192"  href="/peripheral_brain/favicons/android-icon-192x192.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="96x96" href="/peripheral_brain/favicons/favicon-96x96.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/manifest.json">
  <meta name="msapplication-TileColor" content="#748cab">
  <meta name="msapplication-TileImage" content="/peripheral_brain/favicons/ms-icon-144x144.png">
  <meta name="theme-color" content="#748cab">
</head>


<body class="body">
<header>
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
      <ul class="nav-links">
        <li><a href="/peripheral_brain/home.html">Home</a></li>
        <li><a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a></li>
        <li><a href="/peripheral_brain/lab_values">Lab Values</a></li>
        <li><a href="/peripheral_brain/formulas">Formulas</a></li>
        <li><a href="/peripheral_brain/calculators.html">Calculators</a></li>
      </ul>
  </nav>
</header>


<div class="contents">
<h1 class="title">Stable Ischemic Heart Disease (Incomplete)</h1>
<div class="toc">

  <h4>Table of Contents</h4>
  <ul>
  <li><a href="#cardiac-anatomy">Cardiac Anatomy</a>
    <ul>
      <li><a href="#athlerosclerosis">Athlerosclerosis</a></li>
    </ul>
  </li>
  <li><a href="#general-angina">General Angina</a>
    <ul>
      <li><a href="#pathophysiology">Pathophysiology</a></li>
      <li><a href="#oxygen-supply-and-demand">Oxygen Supply and Demand</a></li>
      <li><a href="#risk-factors">Risk Factors</a></li>
    </ul>
  </li>
  <li><a href="#stable-angina">Stable Angina</a>
    <ul>
      <li><a href="#pathophysiology-1">Pathophysiology</a></li>
      <li><a href="#clinical-presentation-and-dx">Clinical Presentation and Dx</a>
        <ul>
          <li><a href="#dx">Dx</a></li>
          <li><a href="#pqrst">PQRST</a></li>
          <li><a href="#common-precipitating-factors">Common Precipitating Factors</a></li>
          <li><a href="#ekg-findings">EKG Findings</a></li>
        </ul>
      </li>
      <li><a href="#treatment">Treatment</a>
        <ul>
          <li><a href="#common-drug-classes-for-treatment">Common Drug Classes for Treatment</a></li>
          <li><a href="#algorithm">Algorithm</a></li>
        </ul>
      </li>
      <li><a href="#anti-platelet-therapy">Anti-Platelet Therapy</a>
        <ul>
          <li><a href="#primary-prevention">Primary Prevention</a></li>
          <li><a href="#secondary-prevention">Secondary Prevention</a></li>
          <li><a href="#dapt-score-and-risk-of-dapt-duration">DAPT Score and Risk of DAPT Duration</a></li>
          <li><a href="#aceis-in-cad">ACEIs in CAD</a></li>
        </ul>
      </li>
      <li><a href="#symptomatic-control">Symptomatic Control</a>
        <ul>
          <li><a href="#acute-nitrates">Acute Nitrates</a>
            <ul>
              <li><a href="#dosing">Dosing</a></li>
            </ul>
          </li>
          <li><a href="#β-blockers">β-Blockers</a></li>
          <li><a href="#ccbs">CCBs</a></li>
          <li><a href="#chronic-nitrates">Chronic Nitrates</a></li>
          <li><a href="#ranolazine">Ranolazine</a>
            <ul>
              <li><a href="#side-effects">Side Effects</a></li>
            </ul>
          </li>
          <li><a href="#ivabradine">Ivabradine</a></li>
        </ul>
      </li>
    </ul>
  </li>
  <li><a href="#prinzmetals-variable-angina">Prinzmetal’s (Variable) Angina</a>
    <ul>
      <li><a href="#pathophysiology-2">Pathophysiology</a></li>
      <li><a href="#treatment-1">Treatment</a>
        <ul>
          <li><a href="#common-drug-classes-for-treatment-1">Common Drug Classes for Treatment</a></li>
        </ul>
      </li>
    </ul>
  </li>
  <li><a href="#unstable-angina">Unstable Angina</a>
    <ul>
      <li><a href="#pathophysiology-3">Pathophysiology</a></li>
      <li><a href="#treatment-2">Treatment</a>
        <ul>
          <li><a href="#common-drug-classes-for-treatment-2">Common Drug Classes for Treatment</a></li>
        </ul>
      </li>
    </ul>
  </li>
</ul>


</div>

<h1 id="cardiac-anatomy">Cardiac Anatomy</h1>

<p><img src="../images/coronaryCirculation.gif" alt="Coronary Arteries" /></p>

<h2 id="athlerosclerosis">Athlerosclerosis</h2>

<p>Athlerosclerosis occluds arteries, and when a large amount of a coronary artery is obstructed, angina can occur. The process of athlerosclerotic development is as follows:</p>

<ol>
  <li>LDL accumulation and oxidation in the wall of a vessel</li>
  <li>Macrophage infiltration and uptake of the LDL deposit</li>
  <li>Formation of foam cells</li>
  <li>Smooth Muscle proliferation and Cap formation</li>
  <li>Cap rupture</li>
  <li>Thrombosis</li>
</ol>

<h1 id="general-angina">General Angina</h1>

<h2 id="pathophysiology">Pathophysiology</h2>

<p>Oxygen demand to cardiac tissue exceeds the ability of coronary circulation to supply oxygen to the cardiac myocytes, leading to ischemia and chest pain</p>

<h2 id="oxygen-supply-and-demand">Oxygen Supply and Demand</h2>

<p><strong>Preload:</strong> Decreased preload is caused by veinous vasodilation, resulting in decreased oxygen consumption and increased myocardial perfusion</p>

<p><strong>Afterload:</strong> Decreased afterload is caused by arterial vasodilation, leading to decreased oxygen consumption</p>

<p><strong>Heart Rate:</strong> Decreased HR leads to decreased oxygen consumption and increased coronary perfusion</p>

<h2 id="risk-factors">Risk Factors</h2>

<ul>
  <li>Age: ≥ 55 for men or ≥ 65 for women</li>
  <li>Smoking</li>
  <li>DM</li>
  <li>HTN</li>
  <li>Kidney Disease</li>
  <li>Obesity</li>
  <li>Sedentary Lifestyle</li>
</ul>

<h1 id="stable-angina">Stable Angina</h1>

<h2 id="pathophysiology-1">Pathophysiology</h2>

<p>Stable angina is a demand ischemia caused by a temporary increase in O<sub>2</sub> demand by cardiac myocytes in the prescense of a diminished O<sub>2</sub> supply, most commonly the result of severe ASCVD leading to significant decreases in blood flow (&gt;70%) through the coronary arteries <strong>without</strong> myocardial necrosis. Stable angina can be of either a fixed threshold, a variable threshold, or both. Stable angina should have stable characteristics for at least 2 months.</p>

<h2 id="clinical-presentation-and-dx">Clinical Presentation and Dx</h2>

<h3 id="dx">Dx</h3>

<ul>
  <li>Look for risk factors</li>
  <li>ST-Depression <strong>During</strong> Angina</li>
  <li>Stress Test</li>
  <li>Cardiac Catheterization</li>
  <li>Electron Beam CT (AHA does not reccomend because results will not change recommendation)</li>
</ul>

<h3 id="pqrst">PQRST</h3>

<ul>
  <li>Precipitating Factors: Exertion etc</li>
  <li>Palliative Measures: Rest and/or SL NTG</li>
  <li>Quality of Pain: Squeezing, heaviness, tightening, etc</li>
  <li>Region and Radiation: Substernal, ocassionally radiating to left arm</li>
  <li>Severity of Pain: Generally &gt;5</li>
  <li>Timing: Typically 5-10min, must be &lt; 20</li>
</ul>

<h3 id="common-precipitating-factors">Common Precipitating Factors</h3>

<ul>
  <li>Cold Air (leads to increased HR)</li>
  <li>Large Meals</li>
  <li>Exertion</li>
  <li>Smoking</li>
</ul>

<h3 id="ekg-findings">EKG Findings</h3>

<p>ST-Depression <strong>only during episodes of angina</strong>, EKG is otherwise unremarkable</p>

<h2 id="treatment">Treatment</h2>

<h3 id="common-drug-classes-for-treatment">Common Drug Classes for Treatment</h3>

<ul>
  <li>Organic Nitrates: Dilation of Venous Blood Vessels to Reduce Preload
    <ul>
      <li>Glyceryl Trinitrate for acute attacks</li>
      <li>IS(M/D)N for prophylaxis</li>
    </ul>
  </li>
  <li>DHP CCBs: Arterial Vasodilation to Decrease Afterload</li>
  <li>Non-DHP CCBs: Negative Inotropy and Chronotropy to Decrease Oxygen Consumption</li>
  <li>β-Blockers: Negative Inotropy and Chronotropy to Decrease Oxygen Consumption</li>
  <li>Ivabradine: Negative Chronotropy via HCN Inhibition to Decrease Oxygen Consumption</li>
  <li>Ranolazine: Inhibits late-Na current to inhibit reverse calcium transport during ischemic attacks</li>
  <li>Statins: Decrease Athlerosclerosis</li>
</ul>

<h3 id="algorithm">Algorithm</h3>

<p><img src="../flowcharts/sihdManagement/sihdManagement.svg" alt="SIHD Management Algorithm" /></p>

<h2 id="anti-platelet-therapy">Anti-Platelet Therapy</h2>

<ul>
  <li>ASA: 75-162mg QD (81mg QD most common)</li>
  <li>Clopidogrel: 75mg BID</li>
  <li>Prasugrel*: 10mg QD</li>
  <li>Ticagrelor*: 90mg BID</li>
  <li>Cangrelor*: IV Only</li>
</ul>

<p><em>*following ACS only</em></p>

<h3 id="primary-prevention">Primary Prevention</h3>

<p>Patients 50-69 with ≥ 10% 10-year CVD risk should be initiated on low-dose aspirin indefinitely if they have no additional bleeding risk. Older patients can continue ASA or initiate ASA; however, shorter life expectancy means the risks may outweigh the benefits. There is insufficient evidencefor a recomendation in patients under 50.</p>

<h3 id="secondary-prevention">Secondary Prevention</h3>

<table>
  <thead>
    <tr>
      <th>Interventions</th>
      <th>Drugs</th>
      <th>Duration</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SIHD</td>
      <td>ASA 81mg QD*^</td>
      <td>Indefinitely</td>
    </tr>
    <tr>
      <td>Elective PCI + BMS</td>
      <td>ASA 325mg before then 81mg QD &amp; Clopidogrel 300-600mg before then 75mg QD</td>
      <td>ASA: Indefinitely; Clopidogrel: Minimum of 1mo, typically 12mo</td>
    </tr>
    <tr>
      <td>Elective PCI + DES</td>
      <td>ASA 325mg before then 81mg QD &amp; Clopidogrel 300-600mg before then 75mg QD</td>
      <td>ASA: Indefinitely; Clopidogrel: Minimum of 6mo, typically 12mo</td>
    </tr>
    <tr>
      <td>PCI/Stent + CABG</td>
      <td>Restart regimine for stent</td>
      <td>ASA: Indefinitely; Repeat duration of stent (i.e. minimum set by kind of stent, 12mo typical)</td>
    </tr>
    <tr>
      <td>CABG</td>
      <td>ASA 81mg QD &amp; Clopidogrel 75mg QD</td>
      <td>ASA Indefinitely; Clopidogrel 12mo</td>
    </tr>
  </tbody>
</table>

<p>*Pts with absolute contraindications or significant intolerance to ASA can initiate Clopidogrel 75mg QD</p>

<p>^DAPT: Dual Antiplatelet Therapy may be given despite lack of evidence in high risk patients</p>

<h3 id="dapt-score-and-risk-of-dapt-duration">DAPT Score and Risk of DAPT Duration</h3>

<table>
  <thead>
    <tr>
      <th>Characteristic</th>
      <th>Points</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Age ≥ 75</td>
      <td>-2</td>
    </tr>
    <tr>
      <td>Age [65,75)</td>
      <td>-1</td>
    </tr>
    <tr>
      <td>Age &lt; 65</td>
      <td>0</td>
    </tr>
    <tr>
      <td>Current Smoker</td>
      <td>1</td>
    </tr>
    <tr>
      <td>DM</td>
      <td>1</td>
    </tr>
    <tr>
      <td>MI at Presentation</td>
      <td>1</td>
    </tr>
    <tr>
      <td>Prior PCI or MI</td>
      <td>1</td>
    </tr>
    <tr>
      <td>Stent Diameter &lt; 3mm</td>
      <td>1</td>
    </tr>
    <tr>
      <td>Paclitaxel-eluting Stent</td>
      <td>1</td>
    </tr>
    <tr>
      <td>CHF with LVEF &lt; 30%</td>
      <td>2</td>
    </tr>
    <tr>
      <td>SVG PCI</td>
      <td>2</td>
    </tr>
  </tbody>
</table>

<p>Scores ≥ 2 favor prolonged therapy, while &lt; 2 have an unfavorable benefit/risk ratio for prolonged therapy (use standard therapy).</p>

<h3 id="aceis-in-cad">ACEIs in CAD</h3>

<p>ACEIs and ARBs have been show to stabilize plaques, improve endothelial function, inhibit smooth muscle migration, decrease macrophage infiltration, and possibly decrease oxidation of LDL. All CAD patients, especially those with CHF with LVEF ≤ 40%, HTN, DM, or CKD should be on an ACEI or ARB.</p>

<h2 id="symptomatic-control">Symptomatic Control</h2>

<h3 id="acute-nitrates">Acute Nitrates</h3>

<p>SL Nitroglycerin is the prefered agent for acute attacks, given as either 0.3-0.6mg SL tabs or 0.4mg/spray SL spray. NTG tablets cannot be stored in vials other than that which they are shipped in, and cannot, by law, have childproof caps.  It is appropriate to have a patient keep a diary of nitrate use to record the frequency of their attacks the the frequency of rescue NTG use.</p>

<h4 id="dosing">Dosing</h4>

<ol>
  <li>Sit Down (Risk of Hypotension)</li>
  <li>Take 1 dose</li>
  <li>Wait 5 minutes</li>
  <li>If pain does not resolve, call 911 and take a second dose</li>
  <li>Take a maximum of 3 doses as needed</li>
</ol>

<h3 id="β-blockers">β-Blockers</h3>

<p>Beta-Blockers work via decreasing myocardial contractility and heart rate, decreasing oxygen demand. Cardioselective agents such as Metoprolol (&lt;100mg dose) and Atenolol (&lt;50mg dose) are prefered, and beta-blocker with intrinsic sympathomimetic activity should be avoided due to the increased resting HR. β-blockers should be dosed to achieve either: RHR 50-60, exercise HR &lt; 100, or exercise HR 75% of HR causing angina. For the specific behavor of β-blockers, see their section in <a href="/peripheral_brain/drugClasses/sympatholytics.html">Sympatholytics</a>.</p>

<h3 id="ccbs">CCBs</h3>

<p>Long acting DHP CCBs or non-DHP CCBs are appropriate therapy choices for prevention of anginal episodes. Consider the distinct behaviors of the DHP (vasodilatory similar to nitrates) and non-DHP (negative inotropes and chronotropes, similar to β-blockers, but with small amounts of vasodilation) classes in determining appropriate therapy. Non-DHPs have the significant and unique monitoring parameter of constipation, especially verapamil. IR DHP CCBs should be avoided due to marked tachycardia.</p>

<h3 id="chronic-nitrates">Chronic Nitrates</h3>

<p>ISDN, ISMN, and transdermal NTG are commonly used. These agents should not be used as monotherapy due to a required washout period of 10-12hrs with no drug on board to prevent tolerance. Other downsides include frequency of administration (BID-QID).</p>

<h3 id="ranolazine">Ranolazine</h3>

<p>Ranolazine inhibits late-Na influx into cardiac myocytes, which during ischemia can change the sodium gradient enough to reverse Ca transport into the cell, creating a positive feedback loop of contraction and damaging the ischemic tissue. Ranolazine has no impact on BP or HR, but can cause <strong>long Q-T intervals</strong>, which has been shown to relate to increased risk of sudden cardiac death. Ranolazine is a third line agent and is typically used in combination with multiple other agents or if adequate control cannot be reached with dual therapy due to decreased HR and BP.</p>

<h4 id="side-effects">Side Effects</h4>

<ul>
  <li>Constipation</li>
  <li>Nausea</li>
  <li>Dizziness</li>
  <li>Headache</li>
  <li>Dose-Dependent QT Prolongation</li>
</ul>

<h3 id="ivabradine">Ivabradine</h3>

<p>Ivabradine can be used off label for angina in adults unable to tolerate β-blockers, with no arrhythmias and a RHR ≥ 70. This medication can also be used in combination with β-blockers if adequate control could not be reached with an adequate β-blocker dose.</p>

<p><strong>CONTINUE HERE WITH COMPELLING INDICATIONS SLIDE 126</strong></p>

<h1 id="prinzmetals-variable-angina">Prinzmetal’s (Variable) Angina</h1>

<h2 id="pathophysiology-2">Pathophysiology</h2>

<p>Prinzmetal’s angina is a supply ischemia resulting from spontaneous vasospasm in the coronary vessels, typically the result of athlerosclerotic insult to the endothelium, leading to a short-lived ischemia. Prinzmetal’s angina typically presents at night when parasympathetic tone is higher.</p>

<h2 id="treatment-1">Treatment</h2>

<h3 id="common-drug-classes-for-treatment-1">Common Drug Classes for Treatment</h3>

<ul>
  <li>Organic Nitrates: Dilation of Venous Blood Vessels to Reduce Preload
    <ul>
      <li>Glyceryl Trinitrate for acute attacks</li>
      <li>IS(M/D)N for prophylaxis</li>
    </ul>
  </li>
  <li>DHP CCBs: Arterial Vasodilation to Decrease Afterload</li>
  <li>Non-DHP CCBs: Negative Inotropy and Chronotropy to Decrease Oxygen Consumption</li>
  <li>β-Blockers: Negative Inotropy and Chronotropy to Decrease Oxygen Consumption</li>
  <li>Ivabradine: Negative Chronotropy via HCN Inhibition to Decrease Oxygen Consumption</li>
  <li>Ranolazine: Inhibits late-Na current to inhibit reverse calcium transport during ischemic attacks</li>
  <li>Statins: Decrease Athlerosclerosis</li>
</ul>

<h1 id="unstable-angina">Unstable Angina</h1>

<h2 id="pathophysiology-3">Pathophysiology</h2>

<p>Unstable angina is supply ischemia characterized by a rapid worsening of athlerosclerosis of a coronary vessel in which the cap of the deposit ruptures, leading to thrombus formation. Unstable angina typically onsets suddenly and typically warns of an impending MI.</p>

<h2 id="treatment-2">Treatment</h2>

<h3 id="common-drug-classes-for-treatment-2">Common Drug Classes for Treatment</h3>

<ul>
  <li>ASA: Decrease Platelt Aggregation / Inhibit Thrombus Formation</li>
  <li>P2Y12 Inhibitors (Clopidogrel, Prasgurel, Ticagrelor): Inhibit Platelt Activation / Inhibit Thrombus Formation</li>
  <li>Heparin: Inhibition of Thrombin via AT-III to inhibit coagulation cascade</li>
</ul>


</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-1-29 <br>
  Last Updated: 2018-2-15</p>
</div>

<footer class="footer menus">
  <nav>
    <ul class="footer-links">
      <li><a href="/peripheral_brain/news_archive.html">News Archive</a></li>
      <li><a href="/peripheral_brain/index.html">Disclaimer</a></li>
    </ul>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
  </nav>
</footer>


</body>
</html>
